Dual‐hormone artificial pancreas for glucose control in type 1 diabetes: A meta‐analysis

Двухгормональная искусственная поджелудочная железа для контроля гликемии при сахарном диабете 1 типа: метаанализ
Baoqi Zeng, Hao Jia, Le Gao, Qingqing Yang, Kai Yu, Feng Sun
2022-05-31

continuous subcutaneous insulin infusiondual-hormone artificial pancreaspredictive low glucose suspendtime in target rangetype 1 diabetes
AIM: To evaluate the efficacy and safety of a dual-hormone artificial pancreas (DH) in type 1 diabetes. MATERIAL AND METHODS: PubMed, Embase, the Cochrane Library and ClinicalTrials.gov were searched for studies published up to February 16, 2022. We included randomized controlled trials that compared DH with single-hormone artificial pancreas (SH), continuous subcutaneous insulin infusion (CSII) or sensor-augmented pumps (SAP), and predictive low glucose suspend systems (PLGS) in type 1 diabetes. The primary outcome was percent time in target (3.9-10 mmol/L [70-180 mg/dL]). Data were summarized as mean differences (MDs) or risk differences (RDs). RESULTS: A total of 17 randomized crossover trials (438 participants) were included. There were nine trials of DH versus SH, 13 trials of DH versus SAP/CSII, and two trials of DH versus PLGS. For time in target, DH showed no significant difference in time in target compared with SH (MD 2.69%, 95% confidence interval [CI] -0.38 to 5.76) but resulted in 16.05% (95% CI 12.06 to 20.05) and 6.89% (95% CI 2.63 to 11.14) more time in target range compared with SAP/CSII and PLGS, respectively. DH slightly reduced time in hypoglycaemia (MD -1.20%, 95% CI -1.85 to -0.56) but increased the risk of gastrointestinal symptoms (RD 0.18, 95% CI 0.08 to 0.27) compared with SH. CONCLUSIONS: The results of this study suggest that DH has a comparable effect on time in target compared with SH, but is associated with a longer time in target range compared with SAP/CSII and PLGS. The DH slightly reduced time in hypoglycaemia but may increase the risk of gastrointestinal symptoms compared with the SH. PROSPERO registration number: CRD42022314015.
1
A meta-analysis included 17 randomized crossover trials involving 438 participants with type 1 diabetes.
2
Compared with SAP/CSII, dual-hormone systems increased time in target by 16.05% (95% CI 12.06 to 20.05).
3
Compared with predictive low-glucose suspend systems, dual-hormone systems increased time in target by 6.89% (95% CI 2.63 to 11.14).
4
Dual-hormone artificial pancreas therapy showed no significant improvement in time in target compared with single-hormone systems (MD 2.69%, 95% CI −0.38 to 5.76).
5
Versus single-hormone systems, dual-hormone therapy slightly reduced hypoglycemia time but increased gastrointestinal symptoms.

Dual-hormone artificial pancreas systems in people with type 1 diabetes

Efficacy and safety of dual-hormone artificial pancreas systems for glycemic control, including time in target range, hypoglycemia, and gastrointestinal symptoms, compared with alternative diabetes technologies

Publication Details
Publication Date
2022-05-31
Journal
Diabetes Obesity and Metabolism
Publisher
Wiley
ISSN
1462-8902
Cited by
32
Access Type
Author Information
Authors
Baoqi Zeng
Hao Jia
Le Gao
Qingqing Yang
Kai Yu
Feng Sun
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%